Pharmaceutical intermediates
Venetoclax Intermediates
3 pharmaceutical intermediates for Venetoclax. Indication: Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell.
About Venetoclax
- Originator
- AbbVie
- Indication
- Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell
- Approved Date
- 04/11/2016
- DS/DP
- 05/26/2030
Available intermediates
3 intermediates currently listed for Venetoclax. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine | 1228780-72-0 | / | / |
| Methyl 4-Fluoro-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzoate | 1235865-75-4 | / | / |
| 3-nitro-4-((tetrahydro-2H-pyran-4-yl)MethylaMino)benzenesulfonaMide | 1228779-96-1 | / | / |
Building toward Venetoclax?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →